Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Sees FY25 operating expenses $92M-$95M. Management also outlined its long-range plan of becoming the recognized ...

Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 first quarter ended December 31, 2024, revenue increased 12.8 percent year-over-year to $81.5 billion. On the basis of U.S. generally ...

FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion.

Vantive builds on a 70-year legacy of kidney care leadership and innovation, with a singular focus on empowering patients and care teams with ...

They had $26 million in collaboration revenue offset by $59.6 million ... may be on the fast track to an approval. Granted, cell therapy companies have shown historically that there is upside ...